PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study

PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study

Drug-induced tumor mutational burden (TMB) may contribute to unleashing the immune response in relatively “immune-cold” tumors, such as sarcomas. We previously showed that PARP1 inhibition perpetuates the DNA damage induced by the chemotherapeutic agent trabectedin in both preclinical models and sar...

Full description

Bibliographic Details
Main Authors: Ymera Pignochino, Giovanni Crisafulli, Giorgia Giordano, Alessandra Merlini, Enrico Berrino, Maria Laura Centomo, Giulia Chiabotto, Silvia Brusco, Marco Basiricò, Elena Maldi, Alberto Pisacane, Valeria Leuci, Dario Sangiolo, Lorenzo D’Ambrosio, Massimo Aglietta, Bernd Kasper, Alberto Bardelli, Giovanni Grignani
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
advanced sarcomas
tumor mutational burden
DNA damage response and repair genes
trabectedin
olaparib
mutational signatures
Online Access:https://www.mdpi.com/2072-6694/13/24/6295

Internet

https://www.mdpi.com/2072-6694/13/24/6295

Similar Items